electroCore, Inc.

Snapshot

electroCore is a small medical-device maker growing revenue fast, $32.0M in FY 2025, up 27.2%, with a strong 86.8% gross margin, but it still lost $14.0M and burned $8.3M in free cash flow. Cash sits at only $10.0M against $9.6M of debt, and Signal8 models roughly 4.6 months of runway.

What's Happening Right Now

• Thu 29th Oct '26 · Earnings date: electroCore will report third-quarter 2026 results after market close on Nov 4, 2026, with a conference call the same day; no figures were disclosed in the notice itself.
• Wed 28th Oct '26 · FDA submission: electroCore submitted a 510(k) to the FDA on Oct 28, 2026 seeking clearance of its Quell device for chronic chemotherapy-induced nerve pain, backed by a 142-subject trial showing roughly 40% symptom improvement versus 24-33% for sham; the device is not yet cleared for this use.
• Wed 28th Oct '26 · EBITDA target: On Oct 28, 2026, co-CEO Joshua Lev said electroCore is targeting positive adjusted EBITDA in the second half of 2027, aiming to get there by expanding its VA, Quell, and chemotherapy-nerve-pain opportunities; this is a stated goal, not a reported result.
• Wed 21st Oct '26 · Investor conference: electroCore presented at Planet MicroCap Toronto 2026 on Oct 27-29, 2026, with co-CEO Joshua Lev delivering the company presentation and hosting investor meetings.
• Wed 9th Sep '26 · Leadership change: On Sept 8, 2026, electroCore named Joshua Lev and Michael Fox co-CEOs following a board succession process, expanded the board to eight members, and adopted amended bylaws tightening proxy-contest advance-notice rules.
• Thu 6th Aug '26 · ATM sale: Sold $86K net / 11K shares through its at-the-market program, as stated for Jul 1, 2026 to Aug 6, 2026.
• Tue 30th Jun '26 · ATM sale: Sold $3.90M net / 495K shares through its at-the-market program, as stated for Apr 1, 2026 to Jun 30, 2026.
• Tue 30th Jun '26 · ATM sale: Sold $3.90M net / 495K shares through its at-the-market program, as stated for Jan 1, 2026 to Jun 30, 2026.